Acutaas Chemicals Limited announced a strong performance for FY2026, with revenue from operations increasing by 33.0% year-on-year to ₹13,394 million. This growth was primarily driven by the Advanced Pharmaceutical Intermediates business, which saw a 37.5% increase, and robust performance in the CDMO segment. EBITDA also saw a significant jump of 107.0% to ₹4,804 million, underscoring the company’s improving profitability and operational efficiency.
Acutaas Chemicals Reports Strong FY2026 Performance
Acutaas Chemicals Limited has declared a robust financial performance for the fiscal year ended March 31, 2026. The company reported a consolidated revenue from operations of ₹13,394 million, marking a significant year-on-year growth of 33.0% over the previous fiscal year’s ₹10,069 million. This substantial increase in revenue highlights the company’s expanding market presence and operational effectiveness.
Key Financial Highlights
The company’s EBITDA also demonstrated remarkable growth, increasing by 107.0% to ₹4,804 million compared to ₹2,321 million in FY2024-25. This surge in EBITDA reflects improved product mix and operational efficiencies. Profit After Tax (PAT) saw a significant rise of 122.2% year-on-year, reaching ₹3,564 million from ₹1,604 million in FY2024-25. The PAT margin improved to 26.6% from 15.9% in the previous year, indicating enhanced profitability.
Growth Drivers
The company’s strong performance was primarily driven by its core Advance Pharma Intermediates business, which recorded a growth of 37.5% on a year-on-year basis, largely attributed to the robust growth in the Contract Development and Manufacturing Organisation (CDMO) segment. Furthermore, the Specialty Chemicals business registered a growth of 8.0%, contributing significantly to the overall revenue. The company’s strategic focus on high-growth sectors and expansion initiatives continue to bolster its market position.
Source: BSE
